Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid in Surgery of Advanced Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females ages 18 or older with a pelvic or abdominal tumor suspected or histopathologically proven ovarian cancer FIGO stage II-IV who are undergoing primary surgery with the intention of performing optimal cytoreductive radical surgery.~* Understand and speak Swedish~* Accept participation in the study after written and verbal information and sign informed consent.~Exclusion Criteria:~* Allergy to tranexamic acid~* Having had tranexamic acid within the recent 30 days~* Previous or present episode of thromboembolic events .~* Previous or present treatment within the recent 3 months with anticoagulant.~* Previous or present known coagulopathy~* Myocardial infarction within the previous 12 months or instable angina pectoris which, according to the investigator, may increase the risk for complications significantly in case of a lowering of the hemoglobin.~* Significant renal failure with serum-creatinine \> 250 µmol/l.~* Severe psychiatric dysfunction or mentally substantially disabled.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- The Tranexamic acid group (Type: ACTIVE_COMPARATOR): The group of women receiving Tranexamic acid intravenously immediately before the surgery
- The placebo group (Type: PLACEBO_COMPARATOR): The group of women receiving saline solution (0.9% NaCl) intravenously immediately before the surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).